Foghorn Therapeutics Inc.
Foghorn Therapeutics discovers and develops medicines targeting chromatin regulatory system dependencies using its Gene Traffic Control platform.
8-KOct 1Latest SEC filing
Oct 1Latest story
October 2026
August 2026
Sign inSign inFoghorn Therapeutics discovers and develops medicines targeting chromatin regulatory system dependencies using its Gene Traffic Control platform.